Mineralys Therapeutics, Inc. $MLYS Shares Acquired by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP increased its position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 65.5% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 69,571 shares of the company’s stock after purchasing an additional 27,546 shares during the quarter. Seven Fleet Capital Management LP owned 0.08% of Mineralys Therapeutics worth $1,885,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the company. RA Capital Management L.P. lifted its holdings in Mineralys Therapeutics by 19.1% in the 3rd quarter. RA Capital Management L.P. now owns 7,323,750 shares of the company’s stock worth $277,717,000 after buying an additional 1,176,470 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Mineralys Therapeutics by 11.1% during the fourth quarter. Vanguard Group Inc. now owns 3,352,880 shares of the company’s stock valued at $121,676,000 after acquiring an additional 333,881 shares in the last quarter. State Street Corp increased its position in shares of Mineralys Therapeutics by 144.4% during the fourth quarter. State Street Corp now owns 3,184,999 shares of the company’s stock worth $115,584,000 after acquiring an additional 1,881,976 shares during the last quarter. Caligan Partners LP increased its position in shares of Mineralys Therapeutics by 37.4% during the third quarter. Caligan Partners LP now owns 2,772,654 shares of the company’s stock worth $105,139,000 after acquiring an additional 755,302 shares during the last quarter. Finally, Orbimed Advisors LLC lifted its stake in shares of Mineralys Therapeutics by 109.4% in the first quarter. Orbimed Advisors LLC now owns 2,052,900 shares of the company’s stock worth $55,613,000 after acquiring an additional 1,072,500 shares in the last quarter. 84.46% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently commented on MLYS shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Friday, July 17th. TD Cowen initiated coverage on Mineralys Therapeutics in a report on Monday, April 27th. They set a “buy” rating on the stock. Jefferies Financial Group reaffirmed a “hold” rating on shares of Mineralys Therapeutics in a research report on Monday, June 1st. Wall Street Zen cut Mineralys Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, HC Wainwright reissued a “buy” rating on shares of Mineralys Therapeutics in a research report on Monday, June 1st. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $49.33.

Insider Transactions at Mineralys Therapeutics

In related news, insider David Malcom Rodman sold 14,056 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $28.58, for a total transaction of $401,720.48. Following the sale, the insider directly owned 63,443 shares of the company’s stock, valued at approximately $1,813,200.94. This represents a 18.14% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jon Congleton sold 75,000 shares of the firm’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $26.14, for a total value of $1,960,500.00. Following the transaction, the chief executive officer owned 614,321 shares in the company, valued at $16,058,350.94. This trade represents a 10.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 237,718 shares of company stock worth $6,218,301. 18.94% of the stock is currently owned by corporate insiders.

Mineralys Therapeutics Stock Performance

Shares of Mineralys Therapeutics stock opened at $25.52 on Friday. Mineralys Therapeutics, Inc. has a 1 year low of $12.59 and a 1 year high of $47.65. The firm’s 50-day simple moving average is $26.88 and its 200-day simple moving average is $27.95. The firm has a market cap of $2.11 billion, a PE ratio of -12.45 and a beta of 0.66.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.04. On average, equities analysts predict that Mineralys Therapeutics, Inc. will post -2.3 earnings per share for the current year.

Mineralys Therapeutics Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.